In this final article on the TRIPS waiver for COVID-19 interventions and technologies, EPR’s Hannah Balfour considers whether it is the correct strategy to overcome COVID-19 treatment inequalities.
By Ayal Ronen (FreeMind Group)
By Ahmed Bouzidi (ProductLife Group)
By Dr Ajaz Hussain, Dr Harsh S. Shah (J-Star Research…
By Hannah Balfour (European Pharmaceutical Review)